Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Kaiser

Showing results (131-140 of 160) with videos related to

Pageof 16
Sort By:
Nature Communications|January 9, 2016
Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myelomaDavid C Johnson, Niels Weinhold, Jonathan S Mitchell, et al.
European Journal of Haematology|May 16, 2017
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysisPhilippe Moreau, Meletios A Dimopoulos, Paul G Richardson, et al.
Insights Into Imaging|October 15, 2023
Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma studySam Keaveney, Alina Dragan, Mihaela Rata, et al.
Cell Reports|September 14, 2017
Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer PolymorphismNi Li, David C Johnson, Niels Weinhold, et al.
Transplantation and Cellular Therapy|June 9, 2021
The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple MyelomaSarah A Holstein, Nizar Bahlis, P Leif Bergsagel, et al.
Lancet (London, England)|December 15, 2018
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trialMeletios A Dimopoulos, Francesca Gay, Fredrik Schjesvold, et al.
Blood Cancer Journal|December 3, 2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentageCarlos Fernández de Larrea, Robert Kyle, Laura Rosiñol, et al.
Haematologica|March 31, 2022
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myelomaSaad Z Usmani, Hareth Nahi, Wojciech Legiec, et al.
BMJ Open|November 17, 2022
Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trialKara-Louise Royle, Amy Beth Coulson, Karthik Ramasamy, et al.
The Lancet. Oncology|October 31, 2020
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion studyChristina Guo, Maxime Chénard-Poirier, Desamparados Roda, et al.
Pageof 16

Showing results (131-140 of 160) with videos related to

Sort By:
Pageof 16
Nature Communications|January 9, 2016
Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myelomaDavid C Johnson, Niels Weinhold, Jonathan S Mitchell, et al.
European Journal of Haematology|May 16, 2017
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysisPhilippe Moreau, Meletios A Dimopoulos, Paul G Richardson, et al.
Insights Into Imaging|October 15, 2023
Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma studySam Keaveney, Alina Dragan, Mihaela Rata, et al.
Cell Reports|September 14, 2017
Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer PolymorphismNi Li, David C Johnson, Niels Weinhold, et al.
Transplantation and Cellular Therapy|June 9, 2021
The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple MyelomaSarah A Holstein, Nizar Bahlis, P Leif Bergsagel, et al.
Lancet (London, England)|December 15, 2018
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trialMeletios A Dimopoulos, Francesca Gay, Fredrik Schjesvold, et al.
Blood Cancer Journal|December 3, 2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentageCarlos Fernández de Larrea, Robert Kyle, Laura Rosiñol, et al.
Haematologica|March 31, 2022
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myelomaSaad Z Usmani, Hareth Nahi, Wojciech Legiec, et al.
BMJ Open|November 17, 2022
Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trialKara-Louise Royle, Amy Beth Coulson, Karthik Ramasamy, et al.
The Lancet. Oncology|October 31, 2020
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion studyChristina Guo, Maxime Chénard-Poirier, Desamparados Roda, et al.
Pageof 16